The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Satellite Symposium | Patient with R/R DLBCL—European perspective

At this year’s European School of Haematology (ESH) ‘2nd How to Diagnose and Treat: Lymphoma’ conference, the Lymphoma Hub hosted a virtual Satellite Symposium on the management and treatment of patients with relapsed/refractory (R/R) lymphoma. Professor Marie José Kersten, Amsterdam UMC, Amsterdam, NL, discussed how she would manage a patient with R/R diffuse large B-cell lymphoma (DLBCL) following relapse to chimeric antigen receptor (CAR) T-cell therapy.

Satellite Symposium | Patient with R/R DLBCL— European perspective

Marie-José Kersten provides an overview of the pivotal clinical trials evaluating CAR T-cell treatments for DLBCL, and the most widely understood mechanisms of resistance to CD19-directed CAR T-cell therapy.

After outlining a number of novel CAR-T constructs, she proceeds to discuss non-CAR T-based therapies and relevant clinical trial opportunities for the patient. These include studies evaluating bispecific antibodies, including epcoritamab and blinatumomab, and the CDK9 inhibitor AZD4573.

Satellite Symposium | Patient with R/R DLBCL— European perspective

If you would like to download the slides from Marie José Kersten's presentation, click below.

Download here